Jacopo Andreose on Angelini Pharma’s strategic evolution: driving innovation, shaping brain health, and humanizing care
In a recent interview with Executive Forecast, Jacopo Andreose, CEO of Angelini Pharma, shared his vision for the company’s ongoing transformation, highlighting a renewed focus on innovation, strategic expansion, and a human-centered approach to healthcare.
With nearly 30 years of global experience, Jacopo joined Angelini Pharma to lead the next phase of its evolution - one that sharpens the company’s focus on research & development and business development & licensing (BD&L), particularly in the central nervous system (CNS) space. While maintaining its broad health portfolio and strong legacy, the company is now actively pursuing a transformational deal to consolidate its presence in key European markets and explore entry into the U.S. with innovative CNS assets.
Angelini Pharma is also committed to shaping the brain health ecosystem. Through partnerships with organizations like The European House – Ambrosetti and the Headway initiative, the company is driving data-backed advocacy and engaging with policymakers to elevate mental health on national and EU agendas.
Italy remains a strategic hub for the company. With major R&D and manufacturing facilities in Ancona, Rome, and Aprilia, Angelini Pharma continues to strengthen its innovation footprint while reinforcing its commitment to the local community and economy.
Crucially, Angelini Pharma is also working to humanize healthcare. The company has created opportunities for employees to hear directly from patients and caregivers, using storytelling and even theatrical performances to deepen empathy and reduce stigma around epilepsy, mental health, and neurological conditions.
“Every patient story reminds us why we do what we do,” Andreose shared. “It’s not just about medicine - it’s about people.”